title: Suboptimal response to imatinib according to 2006-2009 European LeukaemiaNet criteria: a 'grey zone' at 3, 6 and 12 months identifies chronic myeloid leukaemia patients who need early intervention.
authors.forename: Massimo
authors.initials: M
authors.lastname: Breccia
authors.forename: Sonia M
authors.initials: SM
authors.lastname: Orlandi
authors.forename: Roberto
authors.initials: R
authors.lastname: Latagliata
authors.forename: Sara
authors.initials: S
authors.lastname: Grammatico
authors.forename: Daniela
authors.initials: D
authors.lastname: Diverio
authors.forename: Marco
authors.initials: M
authors.lastname: Mancini
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Loglisci
authors.forename: Adriano
authors.initials: A
authors.lastname: Salaroli
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Federico
authors.forename: Michelina
authors.initials: M
authors.lastname: Santopietro
authors.forename: Giuliana
authors.initials: G
authors.lastname: Alimena
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate